GLG News by Nexavar Prescribers: Oncologists

The comprehensive clinical program will supplement the significant body of clinical data existing for ERBITUX in colorectal and head and neck cancers by exploring the use of ERBITUX in additional tumor types including brain, breast, bladder, gastric, lung, pancreas and prostate

The coverage restrictions placed on the FDA-approved indication have no scientific basis and are incompatible with good clinical practice," said Roger M. Perlmutter, M.D., Ph.D., executive vice president of Global Research and Development at Amgen. "We are concerned that inappropriately limiting coverage...

My understading id medicare need to cover all FDA indicated drugs. Here CMS violating FDA indication for Aranesp and procrit

Decrease use by 20-25% use of ESA. This may lead discounting and higher rebate from both amgen and orto-biotech to sustain market share. Since most of amgen contract with aranesp and neulasta use. It may effect use of neulasta. Next 6 month CMS may restrict use of Neulasta and neupogen for neutropenia...

no doubt that Velcade has shown superior results . it deserved to be used as induciton regimen ( unles patient has pre-existing neuropathy)  for transplant. velcade is  more efficacious ,less toxic and more easier to give than VAD regimen.

This is an interesting study, and one that is difficult to perform and get good data. My biggest concern is whether or not the presumed association between diet and skin cancer is actually due to other factors that could also be present in these patients. For example, what if people in this area who...

Vaccine therpy has been of great interest in fight against cancer Vaccine therapy is likely to impact on natural history of cancer?

The mTOR class of drugs are going to be a success for renal cell cancer The mTOR drugs are likely to have broad appeal

Melanoma and breast cancer were chosen because they are the two cancers that most often have sentinel node biopsy done as part of their treatment. Intraoperative lymphatic mapping, or sentinel node biopsy (interchangeable tems for all practical purposes) identifies lymph node metastases at their earliest,...

Torisel is the first mTor drug approved for any indication that I am aware of. Like Sorafenib and Sunitinib, it blocks a biochemical pathway thought to be critical to malignant cell development and survival. These drug are all slightly different and clinically they are probably not direct competitors....